- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic
- Interventions
- Endovascular Stroke Treatment, Medical Management
- Procedure · Other
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,060 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 2,143
matching trials from the local directory fallback.
- Conditions
- Breast Cancer
- Interventions
- Adjuvant Chemotherapy + Ovarian Function Suppression, Ovarian Function Suppression + Aromatase Inhibitor
- Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 3,960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 1226
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more
- Conditions
- Stage III Colon Cancer
- Interventions
- CAPOX 3 month, CAPOX 6 month, Signatera test, mFOLFIRINOX, mFOLFOX6 3-6 month, mFOLFOX6 6 month
- Drug · Device
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1037
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 723 more
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Interventions
- 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
- Procedure
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 45 Years to 70 Years
- Enrollment
- 9,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2065
- U.S. locations
- 478
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 323 more
- Conditions
- Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 211
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more
- Conditions
- Cardiovascular Diseases, Cognitive Impairment, Mild, Dementia
- Interventions
- Atorvastatin 40 Mg Oral Tablet, Placebo oral tablet
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 70 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Wilmington, Delaware + 8 more
- Conditions
- Thrombosis
- Interventions
- Biopspecimen collection, Gruticibart, Placebo, Ultrasound
- Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Best Practice, Biospecimen Collection, Electronic Health Record Review, Survey Administration, Triptorelin Pamoate
- Other · Procedure · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 39 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 201
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
- Conditions
- Pancreatic Carcinoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer
- Interventions
- Androgen Deprivation Therapy, Enzalutamide, Placebo (Sugar Pill), Radical Prostatectomy, Relacorilant
- Other · Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more
- Conditions
- Renal Allograft Recipients
- Interventions
- Belatacept, Corticosteroids, Cyclosporine A, Enteric Coated Mycophenolate Sodium, Mycophenolate Mofetil, Tacrolimus
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- BAG3 Mutation Associated Dilated Cardiomyopathy
- Interventions
- ALXN2350
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Palo Alto, California • Boston, Massachusetts + 4 more
- Conditions
- Blood Protein Disorders, Gene Therapy, Hematologic Disease and Disorders, Hemostatic Disorders, Immune System Disease, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma Progression, Multiple Myeloma in Relapse, Myeloma Multiple, Neoplasm, Neoplasms by Histologic Type, Paraproteinemias, Vascular Disorder
- Interventions
- KLN-1010
- Drug
- Lead sponsor
- Kelonia Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 8
- States / cities
- Duarte, California • Palo Alto, California • San Francisco, California + 5 more
- Conditions
- Aplastic Anemias, Bone Marrow Failure, Hemoglobinopathies
- Interventions
- Not listed
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Not listed
- Enrollment
- 375 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2031
- U.S. locations
- 14
- States / cities
- Duarte, California • Gainesville, Florida • Atlanta, Georgia + 10 more
- Conditions
- Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 26
- States / cities
- Fairhope, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
- Conditions
- Advanced Solid Tumors That Are MTAP Deficient
- Interventions
- AZD3470, Datopotamab deruxtecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- San Francisco, California • West Hollywood, California • New Haven, Connecticut + 5 more
- Conditions
- Transthyretin Amyloid Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Jacksonville, Florida • Chicago, Illinois + 3 more
- Conditions
- Chronic Low Back Pain With a Neuropathic Component, Chronic Pain (Back / Neck), Lumbosacral Radiculopathy, Radiculopathy Lumbar, Sciatica
- Interventions
- Move-MORE
- Behavioral
- Lead sponsor
- National University of Natural Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- Interventions
- Prospective study assessments
- Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more
- Conditions
- Cancer
- Interventions
- Not listed
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- Hip Fractures, Myocardial Injury
- Interventions
- Accelerated medical clearance and surgery
- Other
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 23
- States / cities
- Chandler, Arizona • Davis, California • Irvine, California + 19 more
- Conditions
- Rhabdomyosarcoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Lumbar Puncture, Lymph Node Biopsy, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Resection, Survey Administration, Vincristine Sulfate, Vinorelbine Tartrate
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 50 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 71 more
- Conditions
- Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 332
- States / cities
- Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more